Recent court decisions could make it more difficult for scientists to individually secure usage rights for research involving the study of human biological materials, as patients and clinicians have begun to question exactly what is granted—and to whom it is granted—when a patient signs an informed consent agreement.
Read the complete article by clicking on the link below.
Related Insights
21 May 2025
Tariff & International Trade Resource
What Every Multinational Company Should Know About … Customs Enforcement and False Claims Act Risks (Part III)
We complete the series on “Customs Enforcement and False Claims Act Risks” with Part III, which focuses on preparing for the most common FCA risks arising from improper management of import operations.
02 June 2025
Events
Biotech Panel Discussion & Happy Hour
Join Foley & Lardner LLP along with Biotech XYZ for an engaging evening event featuring a dynamic panel discussion and a lively happy hour.
03 June 2025
Events
Biotech Breakfast + Office Hours
Join Foley & Lardner LLP along with Biotech XYZ for Phase Capitals’ flagship networking biotech breakfast and office hours with Q&A sessions.